The Pharmaceutical Journal
Vol 280 No 7501 p560
10 May 2008

This article
Reprint   Photocopy

  Acrobat Reader

News summary

Tarenflurbil mixed success in AD

Tarenflurbil has shown some benefit in the mild stages of Alzheimer’s disease in a phase II study, published online in The Lancet Neurology (30 April 2008).

In the 210-patient trial, patients with mild disease taking 800mg of the drug experienced slower rates of decline in daily living activities (P=0.033), but not in cognitive function, than those on placebo. Patients with moderate disease did not benefit from treatment.

Tarenflurbil selectively lowers the amyloid-beta peptide Abeta₄₂, thought to be responsible for starting the process of amyloid-beta deposition in the brain in Alzheimer’s disease.